Results 311 to 320 of about 22,374,088 (435)

Therapeutic drug monitoring of imatinib in paediatric chronic myeloid leukaemia: Data from a real‐world setting

British Journal of Haematology, Volume 206, Issue 5, Page 1397-1405, May 2025.
Therapeutic drug monitoring (TDM) of imatinib is reported from a real‐world study in 66 children with paediatric Chronic Myeloid Leukemia (pCML). TDM allows dose adjustments, improving molecular response rates and is a step forward in personalized pCML care.
Meinolf Suttorp, Stephanie Sembill, Phyllis Lensker, Verena Hildebrand, Elke Schirmer, Axel Karow, Manuela Krumbholz, Manfred Rauh, Markus Metzler   +8 more
wiley   +1 more source

Does the Cytogenetic Analysis Using Fluorescence In Situ Hybridization Improve the Preoperative Diagnostic Accuracy of Pancreatic Ductal Adenocarcinoma? [PDF]

Gut Liver, 2020
Kim DU.
europepmc   +1 more source

Myeloid neoplasm inspired intensive therapy in VEXAS syndrome: A single‐centre experience

British Journal of Haematology, EarlyView.
Summary There is still no standard of care and unmet medical needs in refractory/advanced VEXAS (vacuoles in myeloid progenitors, E1 ubiquitin activating enzyme, X‐linked, autoinflammatory manifestations and somatic) syndrome with or without associated haematological neoplasm.
Maël Heiblig, Adriana Plesa, Juliet Tantot, Yvan Jamilloux, Hélène Labussière‐Wallet, Pierre Sujobert   +5 more
wiley   +1 more source

Superficial primitive Ewing's sarcoma: a clinicopathologic and molecular cytogenetic analysis of 14 cases

Modern Pathology, 2009
M. Terrier-Lacombe, L. Guillou, F. Chibon, Gabrielle Gallagher, J. Benhattar, P. Terrier, D. Ranchère, J. Coindre   +7 more
semanticscholar   +1 more source

Comparison of severe aplastic anaemia and lower risk hypoplastic myelodysplastic neoplasms: Critical role of megakaryocyte count in distinguishing aplastic anaemia from myelodysplastic neoplasms

British Journal of Haematology, EarlyView.
In our central morphological review system, megakaryocyte counts are prioritized alongside BM cellularity to differentiate between AA and MDS. A retrospective analysis of patients with SAA and those with LR‐hMDS, registered in that system, revealed a significant difference in outcomes.
Tomoya Maeda, Akira Matsuda, Junya Kanda, Hiroshi Kawabata, Takayuki Ishikawa, Kaoru Tohyama, Akira Kitanaka, Kayano Araseki, Kei Shimbo, Tomoko Hata, Takahiro Suzuki, Hidekazu Kayano, Kensuke Usuki, Maki Shindo‐Ueda, Nobuyoshi Arima, Masaharu Nohgawa, Akiko Ohta, Shigeru Chiba, Yasushi Miyazaki, Shinji Nakao, Keiya Ozawa, Shunya Arai, Mineo Kurokawa, Akifumi Takaori‐Kondo, Kinuko Mitani, the Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes   +25 more
wiley   +1 more source

Real‐life experience of luspatercept in transfusion‐dependent lower risk myelodysplastic syndrome patients

British Journal of Haematology, EarlyView.
This retrospective multicentre study included 98 TD LR‐MDS patients who had failed prior erythropoietin treatment and were subsequently treated with luspatercept. Red blood cell (RBC) transfusion requirements were recorded in the last 16 weeks before luspatercept initiation and response rates consecutively declined in patient groups receiving 1–2 ...
Anthi Bouchla, Sotirios G. Papageorgiou, Ioannis Kotsianidis, Panagiotis Diamantopoulos, Eleni Gavriilaki, Eleni Bouronikou, Argiris Symeonidis, Panagiotis Zikos, Mustafa Cetiner, Efthymia Vlachaki, Akrivi Kostourou, Athanasios Galanopoulos, Eleftheria Hatzimichael, Elisavet‐Christina Vervesou, Sinem Civriz Bozdağ, Nora‐Athina Viniou, Dimitrios Christoulas, Maria Dellatola, Maria Papaioannou, Menelaos Papoutselis, Dimitra Vlachopoulou, Antonia Syrigou, Maria Mainou, Sofia Chatzileontiadou, Vasiliki Pappa   +24 more
wiley   +1 more source

Multiple myeloma with 1q gain/amplification exhibits reduced CD38 expression via interleukin‐6 receptor overexpression

British Journal of Haematology, EarlyView.
Multiple myeloma (MM) with chromosome 1q21 gain/amplification (1q+) has been reported to respond poorly to daratumumab, a human monoclonal antibody targeting CD38. Our findings revealed significantly lower CD38 expression in patients with 1q+ MM than in those with 1q wild type (WT) MM.
Wataru Kuroki, Akihiro Kitadate, Yuto Takahashi, Sayaka Iwama, Masahiro Yamada, Takahiro Kobayashi, Sho Ikeda, Kentaro Narita, Kosei Matsue, Naoto Takahashi   +9 more
wiley   +1 more source

Genomic variant profiling in blast‐phase paediatric chronic myeloid leukaemia: Predisposing and driving alterations

British Journal of Haematology, EarlyView.
To identify pathogenic somatic and germline gene variants associated with blast‐phase transformation and cancer predisposition in paediatric chronic myeloid leukaemia (CML), n = 19 patients with blast‐phase paediatric CML were analysed with whole genome and targeted panel sequencing and compared to n = 19 patients with chronic phase paediatric CML.
Yvonne Lisa Behrens, Thea Reinkens, Winfried Hofmann, Amelie Gumann, Alisa Förster, Laura Gaschler, Tabita Ghete, Renate Strasser, Jennifer Espenkötter, Bernd Haermeyer, Michaela Losch, Stephanie Sembill, Zofia Wotschofsky, Stephan von Hörsten, Wolfgang Schuh, Nataliya Di Donato, Meinolf Suttorp, Manuela Krumbholz, Tim Ripperger, Brigitte Schlegelberger, Gudrun Göhring, Markus Metzler, Axel Karow   +22 more
wiley   +1 more source

A cytogenetic analysis in two species of Cassidinae (Coleoptera, Chrysomelidae). [PDF]

Comp Cytogenet, 2019
Petitpierre E.
europepmc   +1 more source

Cytogenetic analysis of the genus Thoropa Cope, 1865 (Anura-Cycloramphidae) with evolutionary inferences based on repetitive sequences. [PDF]

Genet Mol Biol, 2020
Cholak LR, Haddad CFB, Parise-Maltempi PP.   +2 more
europepmc   +1 more source